Trametinib MAPK inhibitor in ENZA-R pCA - very interesting

Many of us are ENZA resistant in the CRPC phase. In preclinical study in turns out that Trametinib + Enza has a profound effect on proliferation, especially with PTEN loss and PI3K mutations, the pCa is then very dependent on the MAPK signalling pathway. There is a clinical trial II open for new patients, anybody in here on this trial?

aacrjournals.org/cancerres/...

[Benkaymel]

Thanks for sharing this. I'm sure I will be there at some point in the future.